Positive Study for Threshold's Pancreatic Cancer Drug
Posted on: Thursday, 12 January 2006, 15:00 CST
A study by Threshold Pharmaceuticals has shown that glufosfamide can be used safely in conjunction with gemcitabine as a treatment for advanced solid tumors and pancreatic cancer.
The results from the phase I portion of a phase I/II dose-escalation study of glufosfamide in combination with gemcitabine, marketed by Eli Lilly under the brand name Gemzar, have shown glufosfamide to be well-tolerated and to warrant further investigation.
"Based on these encouraging results, we have progressed to the phase II portion of this study to assess the potential for glufosfamide combined with gemcitabine to treat patients with pancreatic cancer who have not previously received chemotherapy," said Alan Colowick, Threshold's chief medical officer.
The phase II portion of the study will investigate the efficacy of glufosfamide in combination with gemcitabine as determined by response rate, duration of response, progression-free survival, overall survival, six and twelve month survival and change in serum tumor marker levels.
Source: Datamonitor
Related Articles
- ThermoDox(R) Liver Cancer Study Phase I Results to Be Presented at ILCA Conference 2008
- Study: More British Preemies Surviving
- AngioDynamics Highlights Study Showing Significant 5-Year Survival After Ablation of Colorectal Liver Metastases
- Study: Live Oaks Losing Survival Battle
- NEOPHARM Presents Updated CINTREDEKIN BESUDOTOX Phase I/II Median Survival Data at European Association of Neuro-Oncology (EANO) Meeting
- Results of Phase II Studies Measure Progression Free Survival for ZACTIMA(TM) (ZD6474) in Lung Cancer
- Study: Ginseng AIDS Cancer Survival
- RenaMed Biologics Reports Positive Phase II Data With Renal Bio-Replacement Therapy; Phase II Study Results Show Improved Survival Rates in Patients With Acute Renal Failure
- Columbia Laboratories Completes Lidocaine Vaginal Gel Pharmacokinetics Study; Phase II Study Planned
- RTOG Study Shows Significantly Improved Survival for Prostate Cancer Patients Treated With Zoladex(R) (Goserelin) Adjuvant to Radiotherapy
 |
 |
User Comments (0)
RSS Feeds